Table 1 Patients information. Clinical characteristics and outcomes to anti PD1 treatment of the study cohort (n = 71)
Age | 60 (33-86) |
Sex, n (%) | |
 male | 35 (49.3) |
 female | 36 (50.7) |
Type of melanoma, n (%) | |
 Cutaneous | 51 (71.8) |
 Uveal | 6 (8.4) |
 Mucosal | 3 (4.2) |
 Unknown origin | 12 (16,9) |
BRAF Status, n (%) | |
 mutated | 34 (47.9) |
 wt | 37 (52.1) |
Previous systemic therapy for metastatic disease, n (%) | |
 yes | 34 (47.9) |
 no | 37 (52.1) |
Stage at metastatic disease, n (%) | |
 M1a | 14 (19.7) |
 M1b | 9 (12.7) |
 M1c | 31 (43.7) |
 M1d | 17 (23.9) |
N. of metastatic sites, n (%) | |
 < 3 | 39 (54.9) |
 ≧3 | 32 (45.1) |
PS (ECOG), n (%) | |
 0 | 32 (45.1) |
 1 | 33 (46.5) |
 2 | 6 (8.4) |
LDH, n (%) | |
 1x ULN | 35 (49.3) |
 2x ULN | 28 (39.4) |
 > 2x ULN | 7 (9.9) |
 Unspecified | 1 (1.4) |
NLR, median (range) | 2.31 (0.83-13.19) |
PLR, median (range) | 141.88 (54.61-518) |
Best response, n (%) | |
 ORR | 29 (40.8) |
 DCR | 33 (46.5) |
 CR | 8 (27.6) |
 PD | 38 (53.5) |
PFS median, months | 4 |
OS median, months | 11 |